Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ear stimulation may boost IVF success – a trial investigates

NCT ID NCT06742788

Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This pilot trial tests whether a non-invasive device that gently stimulates a nerve in the ear, called transcutaneous auricular vagus nerve stimulation (taVNS), is feasible and well-tolerated in people undergoing in vitro fertilization (IVF). The study will enroll 90 infertility patients aged 20 to 40 and compare taVNS to a sham device and no additional treatment. The main focus is on recruitment, adherence, and preliminary pregnancy outcomes, such as clinical pregnancy rates. If successful, this could lead to a larger trial to see if taVNS truly enhances IVF success.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive device that delivers mild electrical pulses to the ear
What this could lead to
If this approach proves feasible and shows promise, it could offer a drug-free, low-risk add-on to IVF that may improve pregnancy outcomes for people with infertility.
What could go wrong
This is a small pilot study focused on feasibility, not proof of effectiveness. The device may not meaningfully improve IVF outcomes, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects aged 20 to 40 years, diagnosed with infertility, and preparing to undergo IVF treatment; 2. Female subjects with anti-Müllerian hormone (AMH) \> 1.2 ng/mL; 3. Scoring at mild-to-moderate levels of impairment on anxiety, and depression scales; 4. Both the subject and their family sign the informed consent form. Exclusion Criteria: 1. The subject had been treated with taVNS in the past; 2. Subjects preparing to undergo frozen embryo transfer; 3. Subjects with a history of mental disorder or who score at a severe level of impairment on anxiety and depression scales; 4. Taking sedatives, anxiety, depression, or psychiatric medications; 5. Comorbidities including arrhythmia, hypertension, diabetes, chronic heart and kidney diseases; 6. Ineligibility for enrollment assessed by a gynecologist or neurologist; 7. Metallic implants or devices contraindicating taVNS.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility assisted reproductive technology are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility assisted reproductive technology

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Xijing Hospital

    RECRUITING

    Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.